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Introduction
Diagnostic Molecular Ultrasound (US) Imaging
• A non-invasive imaging technique to
characterize
biomarkers
within
microenvironment.1

visualize and
the
tumor

• Combine anatomical and physiological information to help
inform treatment plans.2
• The use of microbubble contrast agents (MCAs) to probe
tissue properties does not allow for cellular uptake in
extravascular space.3-5
Phase-changing
Perfluorocarbon
Contrast Agents (PNCAs)

Injection in PAA and Meat Phantoms:

Injection of PNCAs into Phantom Models

In Vivo US Activation and Imaging

• PNCAs w/o Cy7 injected using 25-G and 27-G needles.
• Contrast Enhancement Post-injection – Pre-injection.

• Smaller needle size (27-G) introduced more
spontaneous activation upon injection in both
PAA and tissue-containing models.

• Spontaneous activation of PNCAs was detected
upon injection with 25-G needle (Fig. 5, bottom left).

Injection into athymic nude mice:
• Intra-tumoral injection of Cy7-labeled PNCAs to track
drainage kinetics through lymphatic system (Fig. 2C).
• PA Imaging with an iThera MSOT inVision system.
• Post-mortem fluorescence imaging with Emit Xerra.
• Activate PNCAs w/o Cy7 in vivo using US pulses.
• Intra-muscular injection in the hind limb (Fig. 2C).
• Multiple activation locations based on the injection site.

Nanodroplet

• Imaged and activated by high-clinical-frequency US (Fig. 1).

• Contrast enhancement between pre- and postinjection (Fig. 4):
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• Translate US imaging and activation of optimized PNCAs to
in vivo models through activation and imaging of PNCAs in
phantoms and murine models.

• In vivo activation of optimized PNCAs suggested that
PNCAs are promising molecular imaging targets for
US-mediated multimodality imaging.

Results
US Activation of PNCAs with and without Cy7 dye
• Neither particle experienced
spontaneous activation at
body temperature (Fig. 1C).
• Median Contrast (Fig. 3):

Figure 1. (A) Depiction of PNCA activation. Liquid nanodroplets (ø ~ 250 nm) are exposed
to high amplitude negative pressure waves from focused US transmission and undergo a
phase change to gaseous microbubbles (ø ~ 1.5 μm). (B) Depiction of focused US
transmission to induce phase change of non-activated PNCAs embedded in the PAA
phantom. Upon exposure to spatially targeted US activation pulses, PNCAs are activated
and generate targeted contrast. (C) Representative pre- (top) and post-activation (middle)
pulse-inversion images and a difference (post-activation – pre-activation, bottom) image in
a PAA phantom containing PNCAs without Cy7 dye.

Materials and Methods
Nanoparticle Composition

• Without Cy7: 1.9
• With Cy7:
2.4
• PNCAs without Cy7 showed
greater variance but higher
maximum contrast values.
Figure 3. Contrast in PAA phantoms
containing C6-core PNCAs without
and with Cy7 dye.

• Cy7 can be incorporated into PNCA coatings to allow
for optical tracking in multimodality imaging scans.
Additional investigation is needed to determine if Cy7tagged PNCAs are activated with laser irradiation in
PA imaging.
• Limited spontaneous activation of PNCAs can prove
beneficial to localize the particles prior to selecting
activation locations. However, it is important to ensure
that not all PNCAs activate upon injection.

Figure 2. (A) Diagram of phantom setup for imaging, including PAA phantoms (white),
gelatin-standoff (yellow), water bath (blue), thermocouples (orange) and transducer
footprint (black dashes). (B) Photograph of phantom setup showing the water bath on the
hot plate and depth of thermocouple probes. (C) Depiction of injection experiments,
including the injection into PAA and Meat Phantoms, followed by the injection into the
tongue tumor of an athymic nude mouse to track particle drainage, and the intramuscular
injection into the hind limb of an athymic nude mouse to activate the particles in vivo.

C

Discussion

• The size of needle used for injection could affect
PNCA contrast from US activation due to increased
spontaneous activation with smaller gauge needles.

• Investigate the addition of Cy7 dye to PNCA coating for
optical tracking in both phantom and in vivo models.

B

• Enhancement locations were spatio-temporally
aligned with US activation and particle location.

• PNCAs without Cy7 demonstrated higher variation
across activation locations, likely due to particle age.

Objectives

A

• 1.8 mean image contrast of the activated regions.

• PNCAs with and without Cy7 generate similar
contrast upon US activation in PAA phantoms,
indicating successful Cy7 integration.

B

• PNCA size before activation enables access to tumor cell
surface receptors, followed by a phase (and size) change to
provide US contrast.6-7
• However, localization of PNCAs in vivo is desired prior to
activation.

• Despite this, significant contrast enhancement from
US activation was observed at 2 locations. (Fig. 5,
bottom middle/right).

Figure 4. (A) PIHI image of chicken breast before injection of PNCAs
without Cy7 dye at the center of imaging area using 25-G needle. The cyan
box represents Signal ROI, and the matched blue box laterally adjacent to
the cyan box represents Background ROI. (B) Cropped ROI of the
magenta box from (A) showing contrast enhancement upon injection: preinjection (top) and post-injection (bottom).

Tracking Cy7-Labeled PNCAs In Vivo
• Photoacoustic imaging validated lymphatic
drainage of Cy7-labeled PNCAs after intratumoral injection (Fig. 5A, top).
• Particles were localized in the tongue tumor
immediately after imaging with Xerra and
detected within the sentinel lymph node 2hours post-injection (Fig. 5A, middle/bottom).
• No PNCAs were detected in the contralateral
lymph node (Fig. 5A, bottom).

• Successful injection and activation of PNCAs in vivo
with US-mediated imaging modalities could provide
additional molecular information to clinicians during
intraoperative procedures, such as detection of micrometastases during lymph node biopsy.

Acknowledgement
This
project
was
supported
by
the
Exploratory/Developmental Research Grant (R21) from
the National Institute of Heath (NIH-1R21CA234526).
We thank members of the Bouchard’s Lab and the
CPRIT-CURE Summer Undergraduate Program for
making this summer research project possible.

References

o

• Core: C6-core perfluorocarbon (C6F14, 58 C boiling point).
• Lipid Coating: 97.5% DSPC, 2.5% DSPE-PEG-2000.

A

B

• Cy7 dye conjugated with PEG (for Cy7-labeled PNCAs).
Imaging Setup
• Imaging Platform: Verasonics Vantage 128 system with a
Kolo Medical L22-8v CMUT transducer (15 MHz).
• Data Acquisition: Co-registered B-Mode and PulseInversion Harmonic Imaging (PIHI) with high-frequency US
sequences were used to image (9 MHz, 1 cycle).

Cy7-Labeled
PNCAs

• Focused US pulses were used to activate PNCAs (12 MHz,
6 cycles).

• Imaging and Activation were performed at body temperature
per setup in Fig. 2A, B.
• Contrast from activation was calculated as followed:
Signal – Background
Contrast =
Background
Experimental Design
Polyacrylamide (PAA) Phantom Imaging
• PNCAs with and without Cy7 dye in the coating were
activated and imaged when embedded in a PAA phantom
per standard protocol.

Tumor
Post-injection Xerra image

Cy7-Labeled
PNCAs

Lymph
Node

Xerra image 2 Hours
Post-injection
Figure 5. (A) Photoacoustic imaging showing Cy7-labeled PNCAs drain from the primary tumor after injection (top), as validated post-mortem with white light and
fluorescent imaging (middle and bottom). (B) B-Mode image of Murine hind limb after injection but before activation of PNCAs without Cy7 (top). PIHI images of the
cropped ROI of the yellow box from B-Mode image showing post-activation enhancement (bottom): pre-activation (left), post-activation (middle) and difference
(post-activation – pre-activation, right).
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